Eli Lilly to Buy AtaiBeckley for Up to $3.8B as Pharma Doubles Down on Psychedelics
The Facts
- In July, Eli Lilly announced plans to acquire psychedelic-medicine developer AtaiBeckley for up to US$3.8 billion. Nature only
- AtaiBeckley's lead asset, BPL-003, targets treatment-resistant depression. Nature only
- AbbVie acquired bretisilocin, a short-acting psychedelic developed by Gilgamesh Pharmaceutical, for $1.2 billion in 2025. Nature only
- In 2024 the FDA rejected an application for Lykos Therapeutics' MDMA therapy for PTSD, citing functional unblinding in trials and difficulty separating MDMA's effects from accompanying psychotherapy. Lykos is now Resilient Pharmaceuticals. Nature only
- In July the FDA finalized psychedelic-trial guidance that includes advice for reducing functional unblinding. Nature only
Dive deeper · 3 more factsShow less
- Resilient Pharmaceuticals resubmitted a new-drug application for its MDMA therapy this year. Nature only
- Compass Pathways announced positive results from two late-stage trials of a psilocybin therapy for treatment-resistant depression. Nature only
- Definium Therapeutics released late-stage results in August and September showing its LSD-based pill significantly reduced generalized anxiety disorder symptoms. Nature only
Context
Two years after the FDA rejected MDMA-assisted therapy for PTSD, large pharmaceutical companies are making major investments in psychedelic drug development, according to Nature. Many programs have reached late-stage trials, with findings in anxiety, depression and PTSD.
Researchers credit clearer regulatory guidance worldwide. Scientists quoted by Nature say more research is needed on adverse effects and on how long drug effects must last to be therapeutic, and one cautioned that earlier waves of enthusiasm were halted by the US war on drugs.
How the Agent Panel Scored This
Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 2.
| 6 | Science & Tech Analyst | A up-to-$3.8B pharma acquisition of a psychedelic developer plus several late-stage trial readouts and new FDA guidance is a notable sector shift, but it is a single corporate deal and trial updates rather than immediate broad public impact. |
| 6 | Business Analyst | A up-to-$3.8B pharma acquisition of a psychedelic developer is a notable deal in a growing sector, but it is a single corporate transaction with limited broad market impact and the story is largely a trend roundup citing a single source. |
| 5 | Policy Expert | A pending $3.8B acquisition announced in July plus FDA finalized guidance and trial results are concrete industry actions with moderate sector significance, but the story is largely a trend piece with limited immediate broad impact. |
| 5 | Critical Reader | A pending acquisition announced in July (up to $3.8B) by a major pharma firm is a concrete deal with moderate sector impact, but the story is largely a trend roundup and the deal is not yet closed, with much of the content being background on prior deals and trial results. |
| 5 | Global Affairs Analyst | A concrete up-to-$3.8B acquisition by a major pharma company plus several late-stage trial results and regulatory guidance make this a notable sector development, though it is niche to psychedelic drug investment rather than broad immediate impact. |
| 4 | News Editor | The concrete event is a pharma acquisition of a psychedelic developer for up to $3.8B, a notable deal but limited in direct impact on most people, with the broader trend being more analysis than a single breaking action. |
| 4 | Informed Citizen | A pharma acquisition of a psychedelic developer for up to $3.8B is a notable business and drug-development item with limited immediate impact on ordinary people, since the therapies remain in trials or early regulatory stages. |